Literature DB >> 16597723

Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.

Rainer von Coelln1, Bobby Thomas, Shaida A Andrabi, Kah Leong Lim, Joseph M Savitt, Roya Saffary, Wanda Stirling, Kristy Bruno, Ellen J Hess, Michael K Lee, Valina L Dawson, Ted M Dawson.   

Abstract

Mutations in the genes coding for alpha-synuclein and parkin cause autosomal-dominant and autosomal-recessive forms of Parkinson's disease (PD), respectively. Alpha-synuclein is a major component of Lewy bodies, the proteinaceous cytoplasmic inclusions that are the pathological hallmark of idiopathic PD. Lewy bodies appear to be absent in cases of familial PD associated with mutated forms of parkin. Parkin is an ubiquitin E3 ligase, and it may be involved in the processing and/or degradation of alpha-synuclein, as well as in the formation of Lewy bodies. Here we report the behavioral, biochemical, and histochemical characterization of double-mutant mice overexpressing mutant human A53T alpha-synuclein on a parkin null background. We find that the absence of parkin does not have an impact on the onset and progression of the lethal phenotype induced by overexpression of human A53T alpha-synuclein. Furthermore, all major behavioral, biochemical, and morphological characteristics of A53T alpha-synuclein-overexpressing mice are not altered in parkin null alpha-synuclein-overexpressing double-mutant mice. Our results demonstrate that mutant alpha-synuclein induces neurodegeneration independent of parkin-mediated ubiquitin E3 ligase activity in nondopaminergic systems and suggest that PD caused by alpha-synuclein and parkin mutations may occur via independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597723      PMCID: PMC6674122          DOI: 10.1523/JNEUROSCI.0414-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

Review 1.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

Review 4.  Value of genetic models in understanding the cause and mechanisms of Parkinson's disease.

Authors:  Darren J Moore; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 5.  The role of parkin in familial and sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

6.  Identification and characterization of a novel endogenous murine parkin mutation.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

Review 7.  The PINK1/Parkin pathway: a mitochondrial quality control system?

Authors:  Alexander J Whitworth; Leo J Pallanck
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

8.  Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Li Rebekah Feng; Kathleen Maguire-Zeiss; Gw Rebeck; Hilal A Lashuel; Charbel Eh Moussa
Journal:  Mol Neurodegener       Date:  2010-11-04       Impact factor: 14.195

9.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

10.  Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.

Authors:  Margot Fournier; Jérémie Vitte; Jérôme Garrigue; Dominique Langui; Jean-Philippe Dullin; Françoise Saurini; Naïma Hanoun; Fernando Perez-Diaz; Fabien Cornilleau; Chantal Joubert; Héctor Ardila-Osorio; Sabine Traver; René Duchateau; Cécile Goujet-Zalc; Katerina Paleologou; Hilal A Lashuel; Christian Haass; Charles Duyckaerts; Charles Cohen-Salmon; Philipp J Kahle; Michel Hamon; Alexis Brice; Olga Corti
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.